Holista Colltech Ltd (ASX:HCT): Shares Trade Near 52-Week Low as Half-Year Results Highlight Business Progress

Sonal Goyal

22 September 2026 11:19 PM AEST

Holista Colltech Ltd (ASX:HCT): Shares Trade Near 52-Week Low as Half-Year Results Highlight Business Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Holista Colltech Ltd (ASX:HCT) shares traded at approximately A$0.043 following recent market activity.
The company recorded a daily decline of 4.44%, with shares trading near the 52-week low range.
Holista Colltech reported half-year Revenue of approximately A$2.99 million for the period ended 30 June 2026.
The company operates across dietary supplements, healthy food ingredients, ovine collagen and infection control/agriculture solutions.

Holista Colltech Ltd (ASX:HCT) shares recently traded at approximately A$0.043, recording a daily decline of 4.44% and trading near the company’s 52-week low range. The share price movement reflects recent market activity and is considered separately from the company’s operational developments. Holista Colltech’s latest half-year results update provided information on revenue performance, Margin improvement, divisional activities and financial outcomes for the six months ended 30 June 2026.

Company Business and Operations

Holista Colltech is a health and wellness solutions company operating across four business divisions: dietary supplements, healthy food ingredients, ovine collagen, and infection control/agriculture solutions. The company develops and supplies products across these segments, with operations spanning Australia and Malaysia. Its business activities are focused on developing health-related products, ingredient solutions and specialised applications.

Factors Behind Market Attention

Recent company attention has coincided with the release of Holista Colltech’s half-year results. The company reported group revenue of approximately A$2.99 million for the half-year ended 30 June 2026, representing growth of 3.6% compared with the prior corresponding period. Gross margin improved to 44.3% from 41.9%. These operational updates provide information on business performance, while the share price movement remains separate from the results announcement.

Financial Performance and Future Monitoring Points

Holista Colltech reported revenue of A$2.99 million and a Gross Profit of approximately A$1.33 million during the half-year period. The company recorded a statutory loss after tax of approximately A$2.56 million, compared with a loss of approximately A$0.30 million in the prior corresponding period. The company noted that the result included the impact of a ProImmune legal settlement and related legal fees. Excluding these items, the company reported an Underlying Profit after tax of approximately A$95,000. The Dietary Supplements division recorded revenue growth of 12.2% to approximately A$2.91 million.

Industry and Business Context

Healthcare and wellness companies operate in an environment influenced by consumer demand, product development, regulatory requirements and market competition. Companies in this sector need to maintain product quality, manage Supply chains and respond to changing customer preferences. Holista Colltech’s activities across supplements, ingredients and specialised solutions expose it to trends within multiple health-related markets.

Risks to Consider

Holista Colltech remains exposed to risks including changes in consumer demand, product development challenges, regulatory requirements, supply chain conditions, funding needs and competitive pressures. Financial performance may also be affected by the company’s ability to maintain sales growth, manage costs and execute across its business divisions.

What to Watch Next

Future developments to monitor include divisional sales performance, margin trends, cash management, product initiatives and future financial reporting. Additional company updates will provide further information on operational progress and strategic priorities.

Key Insights

Holista Colltech has recently traded near its 52-week low range as the company continues to develop its healthcare and wellness businesses. The latest half-year results highlighted revenue growth, improved gross margin and divisional performance updates, while also reflecting the impact of one-off settlement-related costs. Future monitoring will focus on sales performance, profitability, Cash Management and additional company disclosures.

FAQs

Q:What caused Holista Colltech’s shares to trade near a 52-week low?

A:The shares traded lower alongside recent market activity. The movement is discussed separately from the company’s half-year results.

Q:What are Holista Colltech’s main business operations?

A:Holista Colltech operates across dietary supplements, healthy food ingredients, ovine collagen and infection control/agriculture solutions.

Q:What recent developments have supported market attention?

A:The company released half-year results showing revenue growth and margin improvement.

Q:What financial factors should be monitored?

A:Key factors include revenue trends, margins, costs, cash management and future financial reports.

Q:What risks could affect the company going forward?

A:Risks include consumer demand changes, regulation, competition, supply chain factors and execution challenges.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.